Сoncentration of IGF-1 and TGF-β in the blood plasma of rats with chronic toxic hepatitis and its correction with lisinopril

Abstract

Materials determining the concentration of IGF-1 and TGF-β in chronic toxic hepatitis and its therapeutic correction with lisinopril are presented in the article. Experimental studies were carried out on 60 non-linear white laboratory rats, with initial body weight of 60-80 g. The animals were divided into 5 groups - 12 rats in each group. Group 1 consisted of intact rats. Chronic toxic hepatitis was modeled in the animals of groups 2, 3, 4 and 5 by intragastric administration of ССl4 Solutio oleosa in the dose of 0.1 ml/100 g of body weight twice a week in combination with 5% ethanol solution for six weeks. The rats of group 2 were administered no other agents. Along with ССl4, the animals of the remaining groups received “Lisinopril” in the dose of 20 mg/kg (group 3), “Glutargin” in the dose of 30 mg/kg (group 4), ССl4 as well as “Glutargin” in the dose of 30 mg/kg and “Lisinopril” - 20 mg/kg (group 5). The study demonstrated increased serum TGF- β and IGF-1levels in rats receiving hepatotoxins, being indicative of chronic inflammation in the liver. Cor- rective combination therapy with lisinopril and glutargin promoted decrease of serum IGF-1 level in rats. The use of lisinopril in experimental CTH resulted in twofold decrease of TGF-β content as compared to untreated animals.